Pharmacogenomics of renin angiotensin system inhibitors in coronary artery disease

Cardiovascular Drugs and Therapy

Volumn 21, Issue 2, 2007, Pages 121-132

  Tsikouris, James P ^a   Peeters, Michael J ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

ACE Inhibitor; Angiotensin II type 1 receptor blocker; Pharmacogenomic; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; IMIDAPRIL; INDAPAMIDE; LOSARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL;

BLOOD VESSEL DIAMETER; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONCEPTUAL FRAMEWORK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG INHIBITION; ENDOTHELIAL DYSFUNCTION; GENOTYPE PHENOTYPE CORRELATION; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; METHODOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTENOSIS; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ARTERIOSCLEROSIS; CORONARY STENOSIS; ENDPOINT DETERMINATION; GENE FREQUENCY; GENOTYPE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ANGIOTENSIN; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 34249752711     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6026-2     Document Type: Review

References (102)

1. The Heart Outcomes Prevention Evaluation Study (HOPE) Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
2. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
3. The Prevention of Events with Angiotensin Converting Enzyme inhibition (PEACE Study) investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
4. Voors AA, van Veldhuisen DJ, van Gilst WH. The current role of ACE-inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice. Cardiovasc Drugs Ther 2006;20:69-73.
5. Ferrari R. ACE inhibition for secondary prevention of cardiovascular events-should we change our recommendation after PEACE? Cardiovasc Drugs Ther 2006;20:11-2.
6. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003;41:159-68.
7. American heart association heart disease and stroke statistics - update 2005. http://www.americanheart.org
8. Allen WL, Johnson JA, Knoell DL, Kolesar JM, McInerney JD, McLeod HL, et al. Pharmacogenomics: applications to patient care. Modules 1, 2, 3. Kansas City, MO:American College of Clinical Pharmacy;2004.
9. Goldstein DB, Weale ME. Population genomics: linkage disequilibrium holds the key. Curr Biol 2001;11:R576-9.
10. Jeunemaitre F, Ledru F, Battaglia S, Guillanneuf MT, Courbon D, Dumont C, et al. Genetic polymorphisms of the renin angiotensin system and angiographic extent and severity of coronary artery disease: the CORGENE study. Hum Genet 1997;99:66-73.
11. Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, et al. Synergistic effects of angiotensin converting enzyme and angiotensin II type I receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994;344:910-3.
12. Kamitani A, Rakugi H, Higaki J, Ohishi M, Shi SJ, Takami S, et al. Enhanced predictability of myocardial infarction in Japanese by combined genotype analysis. Hypertension 1995;25:950-3.
13. Katsuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R, et al. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 1995;345:1600-3.
14. Winkelmann BR, Russ AP, Nauck M, Klein B, Bohm BO, Maier V, et al. Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am Heart J 1999;137:698-705.
15. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism on the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
16. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, et al. Angiotensin converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995;92:1387-8.
17. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-4.
18. Nakai K, Itoh C, Miura Y, Hotta K, Musha T, Itoh T, et al. Deletion polymorphism of the angiotensin-1 converting enzyme gene is associated with serum ACE concentrations and increased risk for CAD in the Japanese. Circulation 1994;90:2199-202.
19. Alvarez R, Reguero JR, Batalia A, Iglesias-Cubero G, Cortina A, Alvarez V, et al. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphism: association with early coronary disease. Cardiovasc Res 1998;40:375-9.
20. Evans AE, Poirier O, Kee F, Lecerf L, McCrum E, Falconer T, et al. Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. Q J Med 1994;87:211-4.
21. Amant C, Bauters C, Bodart JC, Lablanche JM, Grollier G, Danchin N, et al. D allele of the angiotensin I converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 1997;96:56-60.
22. Ribichini F, Steffenino G, Dellavalle A, Matullo G, Colajanni E, Camilla T, et al. Plasma activity and insertion/deletion polymorphism of angiotensin I converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation 1998;97:147-54.
23. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, et al. A prospective evaluation of an angiotensin converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995;332:706-11.
24. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sorensen TI, Jensen G, Tybjaerg-Hansen A. ACE gene polymorphism: ischemic heart disease and longevity in 10,150 individuals: a case referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation 1997;95:2358-67.
25. Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL. A meta-analysis of the deletion allele of the angiotensin converting enzyme gene with myocardial infarction. Circulation 1996;94:708-12.
26. Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L, et al. Large-scale test of hypothesized associations between the angiotensin converting enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival Collaborators. Lancet 2000;355:434-42.
27. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease: Meta-analysis of small and large studies in whites. Arterioscler Thromb Vasc Biol 2000;20:484-92.
28. van Geel PP, Pinto YM, Voors AA, Buikema H, Oosterga M, Crijns HJ, et al. Angiotensin II type 1 receptor A1166C gene polymorphism is associated with and increased response to angiotensin II in human arteries. Hypertension 2000;35:717-21.
29. Lanz JR, Pereira AC, Lemos PA, Martinez E, Krieger JE. Angiotensinogen M235T polymorphism is associated with coronary artery disease severity. Clin Chim Acta 2005;362:176-81.
30. Araujo MA, Goulart LR, Cordeiro ER, Gatti RR, Menezes BS, Lourenco C et al. Genotypic interactions of renin-angiotensin system genes in myocardial infarction. Int J Cardiol 2005; 103: 27-32.
31. Goldenberg I, Moss AJ, Ryan D, McNitt S, Eberly SW, Zareba W. Polymorphism in the angiotensinogen gene, hypertension, and ethnic differences in the risk of recurrent coronary events. Hypertension 2006;48:693-9.
32. Kee F, Morrison C, Poirier O, McCrum E, Mallet C, Nicaud V, et al. Angiotensin II type-I receptor and ACE polymorphisms and risk of myocardial infarction in men and women. Eur J Clin Invest 2000;30:1076-82.
33. Renner W, Nauck M, Winkelmann BR, Hoffmann MM, Scharnagl H, Mayer V et al. Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. J Mol Med 2005;83:235-9.
34. Brown NJ, Vaughn DE. Prothrombotic effects of angiotensin. Adv Intern Med 2000;45:419-29.
35. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-7.
36. Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute myocardial infarction: value of combined thrombolytic and vasodilator therapy. N Engl J Med 1987;317:1055-9.
37. Uren NG, Crake T, Lefroy DC, de Silva R, Davies GJ, Maseri A. Reduced coronary vasodilator function in infracted and normal myocardium after myocardial infarction. N Engl J Med 1994;331:222-7.
38. Kinlay S, Behrendt D, Wainstein M, Beltrame J, Fang JC, Creager MA, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 2001;104:1114-8.
39. Lefroy DC, Crake T, Uren NG, Davies GJ, Maseri A. Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation 1993;88:43-54.
40. Frank MW, Harris KR, Ahlin KA, Klocke FJ. Endothelium-derived relaxing factor (nitric oxide) has a tonic vasodilating action on coronary artery vessels. J Am Coll Cardiol 1996;27:658-63.
41. Weidinger FF, McLenachan JM, Cybulsky MI, Gordon JB, Rennke HG, Hollenberg NK, et al. Persistent dysfunction of regenerated endothelium after balloon angioplasty of rabbit iliac artery. Circulation 1990;81(5):1667-79.
42. Shimokawa H, Aarhus LL, Vanhoutte PM. Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin. Circ Res 1987;61:256-70.
43. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after onset of acute myocardial infarction. Am Heart J 2000;140:324-8.
44. Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
45. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes. J Am Coll Cardiol 1998;31:1460-5.
46. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of c-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
47. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercelloti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-20.
48. Anzai T, Yoshikawa T, Shikira H, Asakura Y, Akaishi M, Mitamura H, et al. C-reactive protein predicts infarct expansion and cardiac rupture after a first Q-wave myocardial infarction. Circulation 1997;96:778-84.
49. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996; 17: 1345-9.
50. Goodfried TL, Elliot ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54.
51. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
52. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54.
53. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (trial on reversing endothelial dysfunction) study. Circulation 1996;94:258-65.
54. O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997;100:678-84.
55. Hornig B, Arakawa N, Haussmann D, Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;98:2842-8.
56. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001;103:799-805.
57. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000;35:60-6.
58. Uehata A, Takase B, Nishioka T, Kitamura K, Akima T, Kurita A, et al. Effect of quinapril versus nitrendipine on endothelial dysfunction in patients with systemic hypertension. Am J Cardiol 2001;87:1414-6.
59. Prasad A, Narayanan S, Husain S, Padder F, Waclawiw M, Epstein N, et al. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation 2000;102:35-41.
60. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000;101:2349-54.
61. Cheetham C, Collis J, O'Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 2000;36:1461-6.
62. Zhang X, Xie Y, Nasjletti A, Xu X, Wolin MS, Hintze TH. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 1997;95:176-82.
63. de Gasparo M. Angiotensin II and nitric oxide interaction. Heart Fail Rev 2002;7:347-58.
64. Carey RM, Wang ZQ, Siragy HM. Update: role of the angiotensin type-2 receptor in blood pressure regulation. Curr Hypertens Rep 2000;2:198-201.
65. Voors AA, van Geel PP, Oosterga M, Buikema H, van Veldhuisen DJ, van Gilst WH. Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. J Renin Angiotensin Aldosterone Syst 2004;5:130-4.
66. Trevelyan J, Needham EW, Morris A, Mattu RK. Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularization versus revascularization alone on systemic endothelial function. Heart 2005;91:1053-7.
67. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94:1247-54.
68. Casterella PJ, Teirstein PS. Prevention of coronary restenosis. Cardiol Rev 1999;7:219-31.
69. Painter JA, Mintz GS, Wong SC, Popma JJ, Pichard AD, Kent KM, et al. Serial intravascular ultrasound studies fail to show evidence of chronic Palmaz-Schatz stent recoil. Am J Cardiol 1995;75:398-400.
70. Mintz GS, Pompa JJ, Pichard AD, Kent KM, Satler LF, Wong C, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996;94:35-43.
71. Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group, Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol 1995;25:362-9.
72. Multicenter European Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction, and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty?. Circulation 1992;86:100-10.
73. Kondo J, Sone T, Tsuboi H, Mukawa H, Kosokabe T, Tsuzuki M, et al. Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound. Am J Cardiol 2001;87:443-5.
74. Meurice T, Bauters C, Hermant X, Codron V, VanBelle E, Mc Fadden EP, et al. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet 2001;357:1321-4.
75. Jorgensen E, Kelbaek H, Helqvist S, Jensen GV, Saunamaki K, Kastrup J, et al. Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2001;38:1434-9.
76. Koch W, Mehilli J, von Beckerath N, Bottiger C, Schomig A, Kastrati A. Angiotensin I-converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene. J Am Coll Cardiol 2003;41:1957-61.
77. Okumura K, Sone T, Kondo J, Tsuboi H, Mukawa H, Tsuzuki M, et al. Quinapril prevents restenosis after coronary stenting in patients with angiotensin-converting enzyme D allele. Circ J 2002;66:311-6.
78. Okamura A, Ohishi M, Rakugi H, Katsuya T, Yanagitani Y, Takiuchi S, et al. Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty. Angiology 1999;50:811-22.
79. Toyofyuku M, Imazu M, Sumii K, Yamamoto H, Hayashi Y, Hiyama K, et al. Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention. Atherosclerosis 2002;160:339-44.
80. Pinto YM, van Glist WH, Kingma JH, Schunkert H. Deletion-type allele of the angiotensin converting enzyme gene is associated with progressive ventricular dilatation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators. J Am Coll Cardiol. 1995; 25:1622-6.
81. Ohmichi N, Iwai N, Maeda K, Shimoike H, Nakamura Y, Izumi M, et al. Genetic basis of left ventricular remodelling after myocardial infarction. Int J Cardiol. 1996;53:265-72.
82. Zee RY, Solomon SD, Ajani UA, Pfeffer MA, Lindpaintner K. Heart investigators. A prospective evaluation of the angiotensin-converting enzyme D/I polymorphism and left ventricular remodeling in the 'Healing and Early Afterload Reducing Therapy' study. Clin Genet 2002;61:21-5.
83. Bis JC, Smith NL, Psaty BM, Heckbert SR, Edwards KL, Lemaitre RN, et al. Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am J Hypertens 2003;16:1011-7.
84. Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J, et al. PROGRESS Collaborative Group. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 2003;42:297-303.
85. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
86. Bleumink GS, Schut AF, Sturkenboom MC, van Duijn CM, Deckers JW, Hofman A, et al. Mortality in patients with hypertension on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism. Pharmacogen Genom 2005;15:75-81.
87. Fournier A, Achard JM, Boutitie F, Mazouz H, Mansour J, Oprisiu R, et al. Is the angiotensin II type 2 receptor cerebroprotective? Curr Hypertens Rep 2004;6:182-9.
88. Lyons D, Webster J, Benjamin N. Effect of enalapril and quinapril on forearm vascular ACE in man. Eur J Clin Pharmacol 1997;51:373-8.
89. Fabris B, Chen B, Pupic V, Perich R, Johnston CI. Inhibition of angiotensin converting enzyme (ACE) in plasma and tissue. J Cardiovasc Pharmacol 1990;15:S6-13.
90. Nakijima T, Yamada T, Setoguchi M. Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992;19:102-7.
91. Fabris B, Yamada H, Cubela R, Jackson B, Mendelsohn FA, Johnston CI. Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats. Br J Pharmacol 1990;100:651-5.
92. Kinoshita A, Urata H, Bumpus M, Husain A. Measurement of angiotensin-I converting enzyme inhibition in the heart. Circ Res 1993;73:51-60.
93. Agema WR, Jukema JW, Zwinderman AH, van der Wall EE. A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias. Am Heart J 2002;144:760-8.
94. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992;51:197-205.
95. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM. Circulating activities of angiotensin converting enzyme, its homolog, angiotensin- converting enzyme 2, and neprilysin in a family study. Hypertension 2006;48:914-20.
96. Smithies O, Kim HS. Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc Natl Acad Sci USA 1994;91:3612-5.
97. Kim HS, Maeda N, Oh GT, Fernandez LG, Gomez RA, Smithies O. Homeostasis in mice with genetically decreased angiotensinogen is primarily by an increased number of renin-producing cells. J Biol Chem 1999;274:14210-7.
98. Smithies O, Kim HS, Takahashi N, Edgell MH. Importance of quantitative genetic variations in the etiology of hypertension. Kidney Int 2000;58:2265-80.
99. Azizi M, Hallouin MC, Jeunemaitre X, Guyene TT, Menard J. Influence of the M235T polymorphism of human angiotensinogen (AGT) on plasma AGT and renin concentrations after ethinylestradiol administration. J Clin Endocrinol Metab 2000;85:4331-7.
100. Brzustowicz LM, Merette C, Xie X, Townsend L, Gilliam TC, Ott J. Molecular and statistical approaches to the detection and correction of errors in genotype databases. Am J Hum Genet 1993;53:1137-45.
101. Goring HH, Terwilliger JD. Linkage analysis in the presence of errors II: marker-locus genotyping errors modeled with hypercomplex recombination fractions. Am J Hum Genet 2000;66:1107-18.
102. Abecasis GR, Cherny SS, Cardon LR. The impact of genotyping error on family-based analysis of quantitative traits. Eur J Hum Genet 2001;9:130-134.